-
Uncategorized1 month ago
Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings
Regeneron hauled in $3.6 billion during the first quarter of 2026, as analysts homed in on a slight Eylea HD miss and key upcoming readouts, including...
-
Uncategorized1 month agoMeet the Researcher: Fred Ramsdell, Nobel winner
Fred Ramsdell is Founder and Advisor, Sonoma Biotherapeutics and one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T...
-
Uncategorized1 month ago
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month...
-
Uncategorized1 month ago
FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death
The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient outside of the country.
-
Uncategorized1 month ago
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
Chiesi Group is taking KalVista Pharmaceuticals under its wing, paying $1.9 billion for the biotech’s oral therapy Ekterly to treat severe swelling episodes caused by the...
-
Uncategorized1 month agoA patent win for Pfizer and BridgeBio
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Several biotech leaders...
-
Uncategorized1 month ago
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
-
Uncategorized1 month ago
AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins
After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly confident that its 2030 revenue target is...
-
Uncategorized1 month ago
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to almost $1.4 billion in the...
-
Uncategorized1 month ago
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug that generated $3.8 billion in the...
